The revenues grew 2% operationally excluding Paxlovid and Comirnaty’s contributions.
In the fourth quarter (Q4) of 2022, they increased 13% operationally to $24.3bn compared to $23.8bn in the same quarter last year.
On an operational basis, the revenues rose by 5%, omitting contributions from Paxlovid and Comirnaty.
The reported diluted EPS for full-year 2022 stood at $5.47, compared to $3.85 in the prior year, indicating a 42% growth.
A 62% rise in adjusted diluted EPS to $6.58 was reported last versus $4.06 in 2021.
For Q4 2022, the reported diluted EPS stood at $0.87 as against $0.59 in the year-ago quarter, indicating a 48% rise.
The company reported a 45% growth in adjusted diluted EPS to $1.14 in the quarter compared to $0.79 in the prior-year quarter.
Pfizer chairman and CEO Dr Albert Bourla said: “2022 was a record-breaking year for Pfizer, not only in terms of revenue and earnings per share, which were the highest in our long history but more importantly, in terms of the percentage of patients who have a positive perception of Pfizer and the work we do.
“As we turn to 2023, we expect to once again set records, with potentially the largest number of new product and indication launches that we’ve ever had in such a short period of time.
“We believe that the combination of these expected near-term launches, additional pipeline products that could potentially come to market in the medium-term, and anticipated contributions from business development, has the potential to set the company up for continued robust growth through the rest of this decade and beyond.”